Clinical Trials

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01593254 2023-06-22

DASCERN

Other hematologic neoplasm

262 enrolled 11 charts

Leukemia, Myeloid, Chronic-Phase

NCT00812240 2023-02-01

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

Phase 3 Terminated

335 enrolled

Phase 4 Not yet recruiting

Neoplasm Metastasis, Gastrointestinal Stromal Tumors

NCT05367765 2022-05-10

A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

2,400 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT00171223 2021-07-22

An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha

LymphoidMyeloidOther hematologic neoplasm

532 enrolled 14 charts

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00171249 2021-07-22

An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia

LymphoidMyeloidOther hematologic neoplasm

293 enrolled 12 charts

Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00171158 2021-06-25

An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis

260 enrolled 4 charts

Blast Crisis, Philadelphia Chromosome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01275222 2021-06-25

Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors

Phase 1/2 Completed

117 enrolled 18 charts

Digestive System Neoplasms, Sarcoma, Stomach Neoplasms, Gastrointestinal Stromal Tumors

NCT02130557 2021-05-18

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

536 enrolled 24 charts 2 FDA

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Pathologic Processes, Philadelphia Chromosome, Translocation, Genetic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03454503 2021-02-23

Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in Egypt

Completed

173 enrolled

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01468688 2020-12-21

A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients

Phase 1 Completed

60 enrolled

Sarcoma

3rd Line GIST

NCT00135005 2020-12-08

Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)

Phase 1 Completed

59 enrolled

Gastrointestinal Stromal Tumors

NCT00471497 2020-11-18

ENESTnd

846 enrolled 33 charts

Bone Marrow Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms

NCT00510354 2020-09-10

Radix

Phase 4 Completed

28 enrolled

Progressive Gastrointestinal Stromal Tumor

NCT02272777 2019-08-19

A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

LymphoidMyeloidOther hematologic neoplasm

225 enrolled 7 charts

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00574873 2019-01-08

Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML

502 enrolled 13 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02204722 2018-06-15

IDEAL

Phase 4 Terminated

55 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00867113 2018-03-14

Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)

91 enrolled 11 charts

Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

NCT00455559 2018-02-22

Ph II Study of Perifosine Plus Gleevec for Patients With GIST

40 enrolled

Gastrointestinal Stromal Tumors

NCT01316458 2017-06-01

Glivec in Prostate Cancer Patients With Rising PSA Following Radical Prostectomy

51 enrolled

Genitourinary

Abdominal Neoplasms, Genital Diseases, Male, Genital Neoplasms, Male, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

NCT01172548 2017-05-31

INV555

132 enrolled

Recurrence, Gastrointestinal Stromal Tumors

NCT00171938 2017-02-24

Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)

Phase 2 Terminated

30 enrolled

CNS

Brain Neoplasms, Glioblastoma

NCT00150072 2017-02-23

Efficacy and Safety of Imatinib in Chordoma

55 enrolled

Sarcoma

Chordoma

NCT00171899 2017-02-23

Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)

Phase 4 Completed

80 enrolled

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00171912 2017-02-23

Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes

MyeloidOther hematologic neoplasmSarcomaThoracic

38 enrolled

Lung Neoplasms, Leukemia, Myelomonocytic, Chronic, Hypereosinophilic Syndrome, Dermatofibrosarcoma, Mastocytosis, Systemic, Leukemia, Myelomonocytic, Juvenile

NCT00481247 2017-02-15

DASISION

547 enrolled 18 charts

Other hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT00372476 2017-02-07

INV181

Phase 4 Completed

33 enrolled

Breast

Breast Neoplasms

NCT02977312 2016-11-30

CCMLJ

Completed

91 enrolled

Leukemia, Myeloid, Chronic-Phase

NCT00427999 2016-11-21

INV342

67 enrolled 6 charts

Genitourinary

Prostatic Neoplasms

NCT00154388 2016-11-18

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

BreastDermatologicGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

185 enrolled

Malignant mesenchymal tumor, Adenocarcinoma, Brenner Tumor, Carcinoma, Renal Cell, Chondrosarcoma, Chordoma, Carcinoma, Adenoid Cystic, Fibroma, Hemangiopericytoma, Hemangiosarcoma, Leiomyosarcoma, Leukemia, Mast-Cell, Liposarcoma, Mastocytosis, Melanoma, Mesothelioma, Multiple Myeloma, Pleural Neoplasms, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Thymoma, Hypereosinophilic Syndrome, Sarcoma, Endometrial Stromal, Dermatofibrosarcoma, Rhabdomyosarcoma, Embryonal, Seminoma, Carcinoma, Ductal, Breast, Neurofibrosarcoma, Primary Myelofibrosis, Small Cell Lung Carcinoma

NCT01483014 2016-11-18

CONVERT

30 enrolled

Gastrointestinal Stromal Tumors

NCT00760877 2016-11-08

Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)

207 enrolled 9 charts